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Abstract
Receptor activity-modifying proteins (RAMPs) serve as oligomeric modulators for numerous G 
protein-coupled receptors (GPCRs), yet elucidating the physiological relevance of these 
interactions remains complex. Receptor activity-modifying protein 2 (Ramp2) null mice are 
embryonic lethal, with cardiovascular developmental defects similar to those observed in mice null 
for canonical adrenomedullin/calcitonin receptor-like receptor (CLR) signaling. We aimed to 
genetically rescue the Ramp2−/− lethality in order to further delineate the spatiotemporal 
requirements for RAMP2 function during development and thereby enable the elucidation of an 
expanded repertoire of RAMP2 functions with Family B GPCRs in adult homeostasis. 
Endothelial-specific expression of Ramp2 under the VE-cadherin promoter resulted in the partial 
rescue of Ramp2−/− mice, demonstrating that endothelial expression of Ramp2 is necessary and 
sufficient for survival. The surviving Ramp2−/− Tg animals lived to adulthood and developed 
spontaneous hypotension and dilated cardiomyopathy, which was not observed in adult mice 
lacking CLR. Yet, the hearts of Ramp2−/− Tg animals displayed dysregulation of Family B 
GPCRs, including parathyroid hormone and glucagon receptors as well as their downstream 
signaling pathways. These data suggest a functional requirement for RAMP2 in the modulation of 
additional GPCR pathways in vivo, which is critical for sustained cardiovascular homeostasis. The 
cardiovascular importance of RAMP2 extends beyond the endothelium and canonical 
adrenomedullin/CLR signaling, in which future studies could elucidate novel and 
pharmacologically-tractable pathways for treating cardiovascular diseases.
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Introduction
Receptor activity-modifying proteins (RAMPs) are single-pass transmembrane proteins that 
physically interact with numerous G protein-coupled receptors (GPCRs) to regulate receptor 
trafficking, ligand binding specificity and downstream G protein coupling and signaling. 
Biochemical and pharmacological studies have revealed functional RAMP interactions with 
many GPCRs including, calcitonin receptor-like receptor (CLR = protein, Calcrl = gene), 
calcitonin receptor (CTR), parathyroid hormone receptor 1 and 2 (PTHR1 and PTHR2), 
glucagon receptor (GCGR), secretin receptor (SCTR), vasointestinal peptide receptor 1 and 
2 (VIPR1 and VIPR2), calcium sensing receptor (CaSR), an estrogen receptor (GPR30), and 
likely additional RAMP-interacting GPCRs will be identified in the future.1–4 Thus, in their 
capacity as endogenous oligomeric GPCR partners, RAMPs can exert powerful modulation 
on nearly every aspect of GPCR function and on a wide range of physiological processes. 
However, our understanding regarding the complexity and consequences of RAMP-GPCR 
interactions in vivo lags behind our current structural, biochemical and pharmacological 
knowledge and thus presents a limitation toward harnessing the potential pharmacological 
utility of this family of proteins.
There exist three mammalian RAMPs, each encoded by single genes, which have been 
systematically knocked out by our laboratory and others.5–7 As expected, based on their 
broad tissue distribution, the phenotypes of Ramp null mice are extensive and largely reflect 
their interactions with multiple GPCRs.8 Ramp1 and Ramp3 null mice survive to adulthood, 
while Ramp2−/− mice exhibit embryonic lethality at mid-gestation due to cardiovascular 
defects in the heart, blood, and lymphatic vasculatures.5–7, 9–11 These phenotypes are 
essentially identical to those observed in mice lacking the genes that encode for CLR and its 
Ramp2-associated ligand, adrenomedullin (AM), indicating that RAMP2 is essential for 
canonical CLR/AM signaling during embryonic development. Yet, mice that are 
haploinsufficient for Ramp2 also exhibit an expanded constellation of endocrine-related 
phenotypes that are not observed in CLR and AM haploinsufficient mouse models.12 
Therefore, these data imply that RAMP2 must exert functional modulation of other GPCRs, 
which is supported by its in vitro biochemical interaction with CTR, PTHR1/2, GCGR, and 
VIPR1/2.2 To date, ascribing a functional relevance for these other putative RAMP2-
interacting GPCR pathways in adult physiological systems has been precluded by the 
embryonic lethality of Ramp2−/− mice.
Here, we have developed a novel Ramp2 transgenic mouse model which overexpresses 
Ramp2 specifically in the endothelium, with the hypothesis that restoration of RAMP2 in the 
endothelium will rescue the lethality-causing vascular defects associated with loss of 
CLR/AM signaling during embryogenesis. Indeed, endothelial RAMP2 is sufficient to 
rescue the embryonic lethality of many Ramp2−/− mice. Thus, the surviving mice, which 
express Ramp2 in the endothelium but lack Ramp2 in every other cell type, provided us with 
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the opportunity to further elucidate the functional implications of the loss of Ramp2 on adult 
cardiovascular physiology and respective changes in other Ramp2-associated GPCRs.
Methods
Mouse Studies
Previously published SvEv-Ramp2+/− and Calcrlflox/flox mice were both fully backcrossed 
(>10 generations) onto a C57BL/6J genetic background for these studies.5, 9 A novel 
endothelial-specific Ramp2 transgenic mouse was generated and crossed to the Ramp2+/− 
mice. All Ramp2 mice used in this study were maintained on an isogenic C57BL/6J genetic 
background. The Calcrlflox/flox mice were crossed with either the SJL-Tg(Tagln-cre)1Her 
(SM22-Cre) or the inducible CAGG-CreERTM mouse to conditionally delete Calcrl 
specifically within developmental vascular smooth muscle cells (vSMC) or ubiquitously in 
adult mice, respectively. Adult CAGG-CreERTM females were administered with tamoxifen 
(TAM) as previously published.13 Genotyping and RT-PCR primers and probes are listed in 
Supplemental Table S1. Females between 4–8 months of age were used in all Ramp2-
associated studies, males 3–4 months of age for vSMC-specific Calcrl studies, and females 
16 month old for ubiquitous Calcrl studies. Mice were acclimated and conscious for both 
non-invasive tail cuff blood pressure and echocardiography analysis and anesthetized with 
isoflurane for intra-arterial blood pressure measurements. Organs weights and heart chamber 
dissections were normalized to either body weight or tibia length as previously described.14 
Biological N of 3–10 mice per genotype was used for each experiment. Endothelial cells 
from adult mice were isolated with magnetic-associated cell sorting using CD31-specific 
antibodies as previously described.15 Cardiomyocytes from adult mice were isolated using 
collagenase digestion as previously described.16 All animal experiments were approved by 
the Institutional Animal Care and Use Committee of The University of North Carolina at 
Chapel Hill.
Statistical Analysis
Statistical analysis was determined with GraphPad 5.0 and data is represented as mean ± 
SEM. The unpaired student T-test was used to compare two groups, while one way ANOVA 
with Tukey’s Multiple Comparison test was used to compare 3 groups. Survival data were 
compared by Mantel-Cox and Gehan-Breslow-Wilcoxon tests. Significant differences are 
represented as * p <0.05, ** p <0.01, ***p <0.001.
Additional detailed methods are provided in the Online Supplemental Data.
Results
Generation and Characterization of Endothelial-Specific Ramp2 Transgenic Animals
A diagram of the Cdh5-Ramp2 transgene (Tg) depicts the murine vascular cadherin 5 
(Cdh5) promoter driving the expression of a flagged-tagged murine Ramp2 cDNA 
(Supplemental Figure S1A), which was successfully integrated into the genome of two 
independent founder lines on the C57BL/6J genetic background. Expression of FLAG-
Ramp2 protein was confirmed using both transgenic founder lines in a variety of adult 
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tissues including the heart, kidney, lung and intestine (Supplemental Figure S1B). Semi-
quantitative RT-PCR revealed the presence of FLAG transcript within whole adult lung 
tissue and CD31+ endothelial-enriched cells in the Tg animals, but not wildtype 
endothelium (Supplemental Figure S1C), which resulted in a modest increase in overall 
Ramp2 gene expression levels within lung CD31+ endothelial cells of Tg animals compared 
to wildtype animals (Supplemental Figure S1D). Ramp2 expression was significantly higher 
in the left ventricles of Tg animals compared to wild-type—a finding which we attribute to 
the endothelial-driven transgene expression, as compared to the low levels of endogenous 
Ramp2 expression in isolated cardiomyocytes (Supplemental Figure S1E) and previously 
reported expression in vSMCs.17, 18 Tg(Cdh5-Ramp2) mice bred normally, with expected 
Mendelian and sex ratios at birth, and no obvious phenotypic defects.
Transgenic Endothelial Ramp2 Partially Rescues Embryonic Lethality of Ramp2−/− Mice
We sought to determine whether endothelial Ramp2 expression could rescue the previously 
reported Ramp2−/− embryonic lethality by interbreeding the hemizygous Tg(Cdh5-Ramp2) 
animals with Ramp2+/− non-transgenic (ntg) animals, on an isogenic C57BL/6J genetic 
background.7, 9 Ramp2+/− Tg(Cdh5-Ramp2) mice (hereafter referred to as Ramp2+/− Tg) 
were crossed to Ramp2+/− ntg animals to generate Ramp2−/− embryos with or without 
expression of the transgene. At e14.5, all six possible genotypes were observed 
(Supplemental Figure S2A). As expected, embryos lacking Ramp2 display non-hemorrhagic 
edema associated with arrested lymphangiogenesis,9 yet the Ramp2−/− Tg embryos showed 
significantly less edema than Ramp2−/− ntg littermates (Figure 1A–B). Unlike the small, 
hypoplastic jugular lymph sacs of Ramp2−/− ntg embryos, the jugular lymph sacs of the 
Ramp2−/− Tg were comparable in size to those of Ramp2+/+ littermates (Figure 1C–D), 
demonstrating that transgenic restoration of functional Ramp2 in the endothelium leads to 
improvement of the edematous phenotype.
In addition to defects in lymphatic development, loss of Ramp2 or AM/CLR signaling leads 
to small, disorganized hearts and thin vSMC walls.9, 19, 20 The aortic endothelium of viable 
embryos appeared intact with no signs of hemorrhagic leakage or endothelial dysfunction as 
previously reported in some Ramp2−/− embryos.7 However, the aortic vSMC layer was 
significantly thinner in Ramp2−/− ntg and Ramp2−/− Tg embryos (Figure 1E–F). Likewise, 
the hearts of e14.5 Ramp2−/− Tg animals were comparable in size to Ramp2−/− ntg 
littermates, which were both significantly smaller than controls, despite detectable 
expression of Ramp2 in Ramp2−/− Tg hearts (Figure 1G–I). Consistent with previous 
reports, these data reflect that Ramp2 expression is required for normal vSMC and cardiac 
development and that endothelial Ramp2 restoration is not sufficient to rescue these defects, 
thus confirming non-endothelial roles of Ramp2 during cardiovascular development.
Unlike the Ramp2−/− ntg embryos, which uniformly die by e15.5, Ramp2−/− Tg embryos 
survive to term at near-Mendelian ratios, but a large number of these animals were found 
stillborn at postnatal day 1 (Supplemental Figure S2B). Nevertheless, by postnatal day 7, 
40% of the expected Mendelian ratio of Ramp2−/− Tg pups were viable, which represents a 
significant survival rescue when compared to the completely penetrant lethality of Ramp2−/− 
ntg mice (Table 1). These surviving Ramp2−/− Tg mice were indistinguishable from 
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Ramp2+/+ littermates (Supplemental Figure S2C). Interestingly, there was a significant 
skewing in the sex ratio of the surviving Ramp2−/− Tg mice, such that 78% were female. 
These data demonstrate that transgenic endothelial restoration of Ramp2 is able to blunt the 
endothelial and edematous phenotypes observed with global Ramp2 genetic deletion, 
leading to significantly improved survival.
Surviving Ramp2−/− Tg Adult Mice are Hypotensive
The surviving Ramp2−/− Tg mice, which express Ramp2 in the endothelium but lack Ramp2 
in all other cells, provided an opportunity to evaluate how Ramp2 loss-of-function during 
development affects adult cardiovascular homeostasis. Diastolic, systolic, and mean arterial 
blood pressures were significantly reduced in Ramp2−/− Tg compared to Ramp2+/+ ntg and 
Tg female controls (Figure 2A). Importantly, there were no significant differences in basal 
blood pressure between Ramp2+/+ ntg and Ramp2+/+ Tg mice, indicating that the decreased 
blood pressure was not caused solely by the transgene. Moreover, the reduced basal blood 
pressure of Ramp2−/− Tg mice was observed without the exogenous administration of the 
canonical, hypotensive ligand AM, which was previously required to lower blood pressures 
in a vSMC-specific overexpression model of Ramp2.21, 22
Similar to the developmental defects in vSMC wall thickness of the Ramp2−/− Tg embryos 
and other models lacking AM/CLR/Ramp2 function,9, 19, 20 the vSMC walls were 
significantly thinner in Ramp2−/− Tg adult descending aortas compared to wild-type controls 
(Figure 2B). Intra-arterial blood pressure measurements further confirmed the hypotensive 
phenotype of adult Ramp2−/− Tg females (Figure 2C). To test vSMC responsiveness, 
Ramp2−/− Tg and controls were challenged with intravenous injections of the α-adrenergic 
receptor agonist, phenylephrine, and the vasodilator, AM. The Ramp2−/− Tg adults were 
capable of normal vasoconstriction and vasodilation as compared to controls (Figure 2C). 
So, although the thinner vSMC walls likely play a role in the hypotensive phenotype of 
Ramp2−/− Tg mice, additional systemic changes likely contribute to the hypotension.
Ramp2−/− Tg Mice Develop Spontaneous Dilated Cardiomyopathy Phenotype
Considering the hypotension and the developmental defects observed in Ramp2−/− Tg 
embryonic hearts, we next assessed how cardiac function and morphology were altered in 
adult Ramp2−/− Tg mice. Echocardiography on conscious mice revealed significantly dilated 
left ventricles during both diastole and systole, with significantly larger left ventricle 
volumes and left ventricle internal diameter dimensions in the Ramp2−/− Tg mice compared 
to Ramp2+/+ and Ramp2+/−, with and without the transgene (Table 2). Representative M-
mode echocardiograms from Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2−/− Tg illustrate the 
ventricular dilation in Ramp2−/− Tg mice (Figure 3A), which resulted in a trending increase 
in calculated cardiac output in these animals (Table 2). Septum and left ventricle posterior 
wall dimensions of Ramp2−/− Tg mice were unchanged from controls, although there was a 
non-significant trend towards a thinner posterior wall. There was also a modest, but 
significant reduction in both ejection fraction and fractional shortening in the Ramp2−/− Tg 
dilated hearts. These data indicate that loss of Ramp2 in non-endothelial cells leads to a 
spontaneous dilated cardiomyopathy (DCM)–like phenotype in adult mice, which at 6 
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months of age had not yet progressed to heart failure, as indicated by the elevated cardiac 
output and sufficient heart function.
Upon dissection, we observed that the hearts of Ramp2−/− Tg mice were grossly enlarged 
compared to wildtype and Ramp2−/− ntg mice (Figure 3B–C). The adult Tg mice had no 
differences in body weight (Ramp2+/+ ntg: 28.4 ± 1.4 g, Ramp2+/+ Tg: 28.4 ± 1.2 g, 
Ramp2−/− Tg: 28.3 ± 1.2 g) or tibia length (Ramp2+/+ ntg: 17.6 ± 0.2 mm, Ramp2+/+ Tg: 
17.9 ± 0.1 mm, Ramp2−/− Tg: 17.8 ± 0.2 mm) regardless of their Ramp2 genotype. Yet, total 
heart weights were significantly larger in the Ramp2−/− Tg mice when normalized to both 
body weight (Figure 3D) or tibia length (Ramp2+/+ ntg: 7.3 ± 0.4 mg/mm, Ramp2+/+ Tg: 6.5 
± 0.2 mg/mm, Ramp2−/− Tg: 9.0 ± 0.3** mg/mm; **p<0.01). Moreover, when normalized 
to body weight the left ventricle (Figure 3E), right ventricle (Figure 3F), and right atria 
(Ramp2+/+ ntg: 0.15 ± 0.01 mg/g, Ramp2+/+ Tg: 0.15 ± 0.01 mg/g, Ramp2−/− Tg: 0.21 
± 0.02* mg/g; *p<0.05) all exhibited significant enlargement in the Ramp2−/− Tg animals 
compared to all other genotypes. Similar significant trends were observed when the 
individual chamber weights were normalized to tibia length (LV:TL; Ramp2+/+ ntg: 5.4 
± 0.3 mg/mm, Ramp2+/+ Tg: 4.8 ± 0.2 mg/mm, Ramp2−/− Tg: 6.5 ± 0.2** mg/mm; 
**p<0.01).
Cross-sectional area of myocytes within the left ventricle revealed slight, but significant 
cardiomyocyte hypertrophy, with no changes in left ventricular capillary density, in the 
Ramp2−/− Tg mice compared to controls (Figure 4A–D). Picrosirius red staining showed no 
differences in perivascular fibrosis, but there was significantly increased interstitial fibrosis 
in the Ramp2−/− Tg hearts compared to hearts of Ramp2+/+ and Ramp2+/+ Tg mice (Figure 
4E–H). There were elevated levels of the oxidative stress indicator, lipid peroxidase 
evidenced by 4-hydroxynonenal (4-HNE) staining in Ramp2−/− Tg hearts (Figure 4I–J).23 
Together, the modest increases in hypertrophy, fibrosis, and oxidative stress, as well as 
modest decline in heart function, further support that 6 month old Ramp2−/− Tg mice exhibit 
a compensated, DCM-like phenotype.
Adult Ramp2−/− Tg Mice Develop Multi-Organ Inflammation
DCM and hypotension can lead to vascular congestion and organ dysfunction throughout the 
body.24–26 Consistently, we observed that the spleen to body weight ratio was significantly 
increased in the Ramp2−/− Tg mice compared to all other genotypes (Figure 5A). Ramp2−/− 
Tg mice also exhibited macroscopic vascular congestion within their livers compared to 
control animals (Figure 5B). Furthermore, multi-organ histology revealed a marked increase 
in the number of inflammatory foci, particularly surrounding the vasculature, within the liver 
(Figure 5C–D), kidney (Figure 5E–F) and lungs (Figure 5G–H). A diagnostic profile of 
adult serum from wildtype and Ramp2−/− Tg mice revealed few significant changes in 
circulating ions or enzyme levels that are typically indicative of hepatocellular or renal 
damage (Supplemental Table S2). This supports that the end-organ inflammation in 
Ramp2−/− Tg mice is likely downstream of altered hemodynamics due to DCM and 
hypotension, rather than primarily due to loss-of-function of Ramp2 in end-organs.
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Conditional Calcrl Deletion Does Not Lead to a Dilated Cardiomyopathy Phenotype
Since CLR and AM represent the most well-characterized, canonical pathway for RAMP2 
modulation and the knockout mice for these genes recapitulate the Ramp2−/− developmental 
phenotypes, it is reasonable to consider that disruption of this pathway, which has been 
demonstrated to be cardioprotective in both animal studies and in humans,27–30 may 
underlie the DCM and hypotensive phenotypes in Ramp2−/− Tg mice. To test the functions 
of CLR in non-endothelial cells, we generated cardiac- and vSMC-specific Calcrl null mice 
using the SM22-Cre mediated excision. The CalcrlloxP/loxP; SM22Cre+ mice were born at 
expected Mendelian ratios and survived to adulthood (Supplemental Figure S3A). Relative 
Calcrl expression was significantly reduced in aortic vSMCs and hearts of CalcrlloxP/loxP; 
SM22-Cre+ compared to CalcrlloxP/+; SM22-Cre+ littermates (Supplemental Figure S3B). 
Importantly, CalcrlloxP/loxP; SM22-Cre+ adult males were normotensive and had no basal 
changes in heart function, size, or morphology (Supplemental Table S3 or Figure S3C). 
Similarly, cardiac-specific Calcrl deletion using the αMHC-Cre+ transgenic line also failed 
to recapitulate the DCM phenotype, with animals surviving to adulthood with no basal 
cardiac dysfunction (Dackor R & Caron K.M., unpublished data, [2016]). These data 
demonstrate that cardiac- and vSMC-specific Calcrl expression is not required for 
embryonic development or adult cardiovascular maintenance.
We have previously shown that temporal, global deletion of Calcrl in adult CalcrlloxP/loxP; 
CAGG-CreERTM mice results in dilated lymphangiectasia in many lymphatic vascular beds 
throughout the body.13 However, these mice did not display any obvious cardiac phenotypes 
and they had similar heart to body weight ratio as TAM-injected control mice 
(CalcrlloxP/loxP; CAGG-CreERTM: 4.43 ± 0.19 mg/g versus Calcrlflox/flox: 4.13 ± 0.14 mg/g, 
respectively). Furthermore, conscious echocardiography of CalcrlloxP/loxP; CAGG-CreERTM 
female mice, even at 14 months of age, failed to reveal any significant changes in left 
ventricle internal diameter, function, or heart size compared to control mice (Supplemental 
Table S4). Collectively, these data, generated from three independent series of conditional 
deletion approaches, indicate that the global-, cardiac- or vSMC-specific loss of Calcrl does 
not recapitulate the DCM phenotype observed in the Ramp2−/− Tg animals. Therefore, this 
strongly suggests that the Ramp2−/− Tg phenotype is imparted by other RAMP2-associated 
GPCR pathways.
Ramp2−/− Tg hearts exhibit reduced signaling pathways and expression of numerous 
RAMP-associated GPCRs
The genetic reduction or down-regulation of the transcriptional regulator CREB25, 31 and the 
crucial PPAR pathway transcription factor, Pgc-1α,32–34 have both been shown to be 
involved in DCM pathogenesis. Thus as expected, the relative expression of Pgc-1α was 
significantly down-regulated in left ventricles and in an enriched cardiomyocytes fraction of 
Ramp2−/− Tg hearts compared to controls (Figure 6A–B). There was also a significant 
reduction in phosphorylated CREB compared to total CREB and Gapdh in the Ramp2−/− Tg 
hearts compared to Ramp2+/+ ntg and Ramp2+/+ Tg hearts (Figure 6C). Numerous Family B 
GPCRs signal through these pathways, including the Gcgr which has been shown to signal 
through cAMP to activate both CREB and PPAR transcription,35–38 and both the Pthr1 and 
CaSR signal through cAMP and CREB.39–41 Interestingly, the gene expression levels of 
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these RAMP-associated GPCRs were significantly down-regulated in the left ventricles of 
Ramp2−/− Tg mice compared to those of control animals, whereas genes encoding for other 
RAMP-associated GPCRs, like Calcr, Vipr1, and Gpr30, were unchanged (Figure 6D).
Similar gene expression changes in these Family B GPCR expression profiles were 
confirmed in isolated cardiomyocyte fractions (Figure 6E), further supporting the myocyte-
specific genetic dysregulation. Calcrl expression was significantly increased in left ventricle, 
but not in the cardiomyocyte-enriched fraction, demonstrating that Calcrl upregulation is 
from a non-cardiomyocyte cell type. The expression of both Pthr1 and Gcgr were 
significantly decreased during development in the hearts of Ramp2−/− ntg and Ramp2−/− Tg 
embryos (Figure 6F), supporting that these changes are specific to Ramp2 loss rather than 
secondary to the Cdh5-driven Ramp2 Tg or the DCM phenotype, as might be the case for 
CaSR. Serum analysis revealed no significant dysregulation of circulating calcium or 
glucose, thereby eliminating uncompensated Pthr1 or Gcgr systemic signaling as a cause for 
the cardiovascular phenotypes (Supplemental Table S2). Collectively, these data demonstrate 
that genetic loss of Ramp2 in non-endothelial cells of the heart leads to down-regulation of 
both RAMP2-associated GPCRs, Gcgr and Pthr1, as an underlying mechanistic basis for the 
decreased pCREB and Pgc-1α responsible for the pathogenesis of the DCM-like phenotype 
in Ramp2−/− Tg mice (Figure 6G).
Discussion
In this study, we generated an endothelial-specific Ramp2 Tg mouse model to attempt to 
rescue the embryonic lethality due to global loss of Ramp2. While no Ramp2 null mice 
survive to birth, we observed a significant number of Ramp2−/− Tg born and able to survive 
into adulthood. This result further confirms that endothelial Ramp2 is essential for 
embryonic survival and represents, to our knowledge, the first genetic rescue of the global 
Ramp2 null lethality.
It remains unclear why a significant number of Ramp2−/− Tg pups survive to late-gestation, 
but are stillborn. Interestingly, it was recently shown that mice with endothelial excision of 
Ramp2 during development using a Cdh5-Cre died during late-gestation.24 Additionally, 
they report that approximately 5% of the endothelial Ramp2 knockouts live into adulthood 
and develop large hearts, hypotension, and multi-organ vasculitis. In this current study we 
found that 40% of Ramp2−/− Tg survived to adulthood, and also developed similar 
cardiovascular and inflammatory phenotypes. These two mouse models, as well as a 
previously published endothelial-specific deletion of Calcrl, demonstrate that adequate levels 
and timing of endothelial Ramp2/CLR/AM signaling are critical for embryonic survival.9
In addition, these studies identify potential sex-dependent mechanisms of Ramp2, or Cdh5, 
regulation and function, as evidenced by the substantially reduced numbers of male 
Ramp2−/− Tg survivors. We have previously shown that adult Ramp2+/− females have 
endocrine phenotypes not present in Ramp2+/− males.12 In addition, Ramp3−/− males, but 
not females, displayed exacerbated cardiovascular phenotypes when challenged with 
hypertension.4, 10 Thus, while RAMP2 and RAMP3 interact with both similar and different 
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GPCRs, our observations of sex-dependent phenotypes in these genetic animals will provide 
an area for interesting future investigations.
The complex compensatory mechanisms through which RAMP-mediated AM/CLR 
signaling regulate blood pressure have not been fully elucidated. It is well documented that 
AM infusion acts to lower blood pressure through both vSMC and endothelium, but it 
remains disputed if altered AM expression using genetic models alters basal blood 
pressure.18, 42–45 Moreover, while developmental loss of Ramp2 leads to spontaneous 
hypotension and adult Ramp1−/− mice develop hypertension.11, 24 Calcrl deletion in vSMC 
and cardiomyocytes appears dispensable for regulation of basal vascular tone in adult males. 
It is evident that Ramp2 and AM signaling plays a role in vSMC and myocardium 
development and function, which likely contributes to the pathogenesis of hypotension and 
DCM in Ramp2−/− Tg survivors. Yet, the hypotension and DCM phenotypes occur despite 
maintenance of normal cardiac output. It is further possible that the developmentally-
induced thin vSMC walls contribute to reduced vascular tone; however we demonstrated 
their ability to effectively respond to acute phenylephrine vasoconstriction. Therefore, 
additional studies that explore the entire repertoire of RAMP-mediated GPCRs will be 
required for full elucidation of the mechanistic basis for the hypotension in Ramp2−/− Tg 
survivors.
Loss of Ramp2 in multiple non-endothelial cardiac cells, along with altered humoral 
signaling could lead to cardiac dysfunction and DCM pathogenesis. The genetic 
dysregulation in isolated cardiomyocytes suggests roles of Ramp2/GPCRs specifically in 
cardiomyocytes. Interestingly, a recently published study demonstrated that a 
cardiomyocyte-specific Ramp2 deletion led to a DCM-like phenotype due to mitochondrial 
dysfunction and irregular calcium handling, which the authors attribute to loss of CLR/AM 
signaling.46 Similarly, this study suggests that cardiomyocyte loss of Ramp2 in the 
Ramp2−/− Tg mice is likely responsible for the DCM. Moreover, our data demonstrates that 
neither cardiomyocyte- or vSMC-specific loss of Calcrl during development or conditional 
Calcrl deletion in adults recapitulate the DCM phenotype observed in the Ramp2−/− Tg and 
the aforementioned Ramp2flox/flox; αMHC-MerCreMer mice.46 Therefore, collectively, 
these studies imply the involvement of other RAMP-associated GPCRs.
It is apparent that RAMPs interact with numerous GPCRs biochemically, although in vivo 
physiologic evidence of these interactions is limited. We found that lack of Ramp2 in non-
endothelial cells leads to decreased expression of cardiac Pthr1 and Gcgr. Interestingly, 
human PTHR1 and GCGR interact specifically with RAMP2 and not RAMP1 or RAMP3 in 
which RAMP2 is important in chaperoning both GPCRs to the plasma membrane.2 
Furthermore, it was recently demonstrated that RAMP2 was important in GCGR ligand 
selectivity between glucagon and glucagon-like peptide 1, which have opposing physiologic 
effects on glucose homeostasis and cardiovascular function.47 While GCGR has not been 
directly connected to DCM pathogenesis, glucagon can alter calcium signaling in myocytes 
and glucagon-like peptide 1 improves glucose uptake and survival of canines with 
DCM.35, 48 Likewise PTHR1 signaling is important in vitamin D and calcium homeostasis, 
which have both been associated with DCM.49, 50 Together, Ramp2 loss-of-function can not 
only alter both Pthr1 and Gcgr expression simultaneously, but may also alter their ability to 
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reach plasma membrane, bind ligands, and signal. Additionally, we observed decreased 
signaling through CREB and downregulation of Pgc-1α, which both have been shown to 
lead to DCM.25, 31, 32 Both Pthr1 and Gcgr signal through CREB and murine deletion of 
Gcgr led to decreased phosphorylated CREB and Pgc-1a expression levels.36, 38 Thus, loss 
of Ramp2 likely has numerous mechanisms for the development and maintenance of cardiac 
functions both dependent and independent of canonical AM/CLR/Ramp2 signaling.
Perspectives
The in vivo interplay between GPCR/RAMP/Ligand is highly complex and is only starting 
to be understood. However, a better understanding of these interactions in a spatial and 
temporal manner in a pathophysiologic context will help us better target the unique GPCR/
RAMP interfaces to potentially treat disease like DCM and hypertension.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Novelty and Significance
What Is New?
• Using a novel genetic mouse model, we find that endothelial expression 
of receptor activity-modifying protein 2 (Ramp2) is able to rescue the 
embryonic lethality of Ramp2−/− mice.
• Ramp2 loss-of-function leads to spontaneous hypotension, dilated 
cardiomyopathy, and multi-organ inflammation, which we show are not 
recapitulated in genetic models with loss of calcitonin-receptor-like 
receptor (CLR) signaling.
• In vivo loss of Ramp2 causes dysregulation of numerous RAMP-
associated GPCRs, including the glucagon and parathyroid hormone 
receptors.
What is Relevant?
• The physiological consequences of RAMP interactions with Family B 
GPCRs have been challenging to address due to the embryonic lethality 
of RAMP2 mice. Here, we elucidate the importance of RAMP2 
interactions with several GPCR pathways, which can ultimately 
provide novel targets, or predict off-target consequences, for 
pharmacological therapies against cardiovascular disease.
Summary
This study provides genetic in vivo evidence that endothelial Ramp2 expression is 
necessary and sufficient to rescue the lethality of global loss of Ramp2. Ramp2 
expression in non-endothelial cells during development is required to maintain adult 
blood pressure and cardiac homeostasis—a process that involves numerous GPCR 
signaling pathways, including glucagon and parathyroid hormone receptor signaling. 
Collectively, these studies extend the functional repertoire of RAMP-associated receptors 
in cardiovascular physiology.
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Figure 1. Endothelial restoration of Ramp2 partially rescues embryonic edema leading to 
prolonged survival of Ramp2−/− mice
(A) Representative images and (B) quantification of edema severity from e14.5 Ramp2+/+, 
Ramp2−/− ntg, and Ramp2−/− Tg embryos. Edema scoring system: (1) no edema, (2) mild 
edema, and (3) severe edema. (C) Immunohistochemistry and (D) quantification of jugular 
lymph sac size using Lyve1 (green) and DAPI (magenta). CA, carotid artery; JV, jugular 
vein; JLS, jugular lymph sac. (E) Histology of descending aortas and (F) quantification of 
aortic vSMC wall thickness. (G) Heart histology, (H) quantification of ventricle area, and (I) 
whole heart relative Ramp2 expression from viable Ramp2+/+ ntg, Ramp2−/− ntg, and 
Ramp−/− Tg e14.5 embryos. Samples were normalized to Ramp2+/+ ntg and Gapdh 
expression. Scale bars: 100 μm. Data represented as average ± SEM from N = 3–8 mice per 
genotype. Significance determined by one-way ANOVA with Tukey’s Multiple Comparison 
with *p<0.05, **p<0.01, and ***p<0.001.
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Figure 2. Ramp2−/− Tg adults are hypotensive
(A) Tail-cuff telemetry blood pressure analysis from conscious Ramp2+/+ ntg, Ramp2+/+ Tg, 
and Ramp2−/− Tg adult female mice. (B) Representative images and vSMC wall thickness 
quantifications of Ramp2+/+ ntg and Ramp2−/− Tg descending aortas. Scale Bars: 100 μm. 
(C) Intra-arterial blood pressure measurements from anesthetized Ramp2+/+ ntg, Ramp2+/+ 
Tg, and Ramp2−/− Tg mice during baseline and after challenged with intravenous bolus of 
30 μg/kg phenylephrine (PE) or 12 nmol/kg adrenomedullin (AM). Drug response 
represented as a % change from baseline (dotted line). Data represented as average ± SEM 
from N = 3–5 mice per genotype. Significance determined by one-way ANOVA with 
Tukey’s Multiple Comparison (A, C) or unpaired student T-test (B) with *p<0.05 and 
**p<0.01.
Kechele et al. Page 16
Hypertension. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Ramp2−/− Tg adults develop spontaneous dilated cardiomyopathy
(A) Representative M-mode echocardiograms from left ventricles of Ramp2+/+ ntg, 
Ramp2+/+ Tg, and Ramp2−/− Tg mice. Macroscopic (B) and H&E (C) images of whole 
hearts and left ventricles from of Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2−/− Tg mice. Scale 
Bars: 2 mm. Quantification of heart (D), left ventricle (E), and right ventricle (F) weight 
normalized to body weight. Data represented as average ± SEM from N = 4–10 mice per 
genotype. Significance determined by one-way ANOVA with Tukey’s Multiple Comparison 
with *p<0.05, **p<0.01, ***p<0.001.
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Figure 4. Ramp2−/− Tg left ventricles hypertrophied with early fibrotic and oxidative stress 
changes
(A) Histology and (B) wheat germ agglutinin (WGA, white) immunohistochemistry 
showing cardiomyocytes from Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2−/− Tg left 
ventricles. Quantification of (C) cardiomyocyte cross-sectional area and (D) capillary 
density from mouse left ventricles. Representative images and quantification of left 
ventricles stained with Picrosirius Red showing (E–F) perivascular and (G–H) interstitial 
fibrosis/collagen deposition. (I) Immunohistochemistry and (J) quantification of 4-HNE 
(white) staining showing relative levels oxidative stress in left ventricles. Scale Bars: 100 
μm. Data represented as averages ± SEM from N = 3–4 mice per genotype. Significance 
determined by one-way ANOVA with Tukey’s Multiple Comparison with *p<0.05 and 
**p<0.01.
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Figure 5. Ramp2−/− Tg have vascular congestion and multi-organ inflammation downstream of 
hypotension and dilated cardiomyopathy
(A) Spleen to body weight ratio from Ramp2+/+, Ramp2+/−, and Ramp2−/− females with and 
without the transgene. (B) Macroscopic images of liver vasculature abnormalities in 
Ramp2−/− Tg compared to that of Ramp2+/+ ntg and Ramp2+/+ Tg controls. Histology and 
quantification of inflammatory foci (blue arrows) in (C–D) livers, (E–F) kidneys, and (G–
H) lungs from Ramp2+/+ ntg, Ramp2+/+ Tg, and Ramp2−/− Tg mice. Scale Bars: 1 mm (B) 
and 100 μm (C, E, G). Data represented as averages ± SEM from N = 3–4 mice per 
genotype. Significance determined by one-way ANOVA with Tukey’s Multiple Comparison 
with *p<0.05, **p<0.01, ***p<0.001.
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Figure 6. Decreased signaling and expression of RAMP-associated GPCRs in embryonic and 
adult Ramp2−/− Tg hearts
RT-PCR showing relative Pgc-1α expression from Ramp2+/+ ntg, Ramp2+/+ Tg, and 
Ramp2−/− Tg adult left ventricle (A) or cardiomyocytes (B). (C) Quantification and 
representative western blot of phosphorylated CREB to total CREB in Ramp2+/+ ntg, 
Ramp2+/+ Tg, and Ramp2−/− Tg left ventricles. Samples were normalized to Ramp2+/+ ntg 
and CREB with Gapdh used as a loading control. Relative expression of the Family B 
GPCRs; Calcrl, Calcr, Pthr1, Gcgr, Vipr1, CaSR and Gpr30 in (D) whole left ventricles and 
(E) isolated cardiomyocytes from adult Ramp2−/− Tg mice and Ramp2+/+ controls. (F) 
Relative GPCR expression from e14.5 Ramp2+/+ ntg, Ramp2−/− ntg, and Ramp2−/− Tg 
whole hearts. Samples were normalized to Ramp2+/+ ntg and Gapdh and Rpl19 expression. 
(E) Data represented as averages ± SEM from N = 3–5 mice per genotype. Significance 
determined by one-way ANOVA with Tukey’s Multiple Comparison (A, C, D, F) or 
unpaired student T-test (B, E) with *p<0.05. (F) Model summarizing cardiovascular 
phenotypes in Cdh5+ endothelium and Cdh5- cells in Ramp2+/+ ntg, Ramp2+/+ Tg, and 
Ramp2−/− Tg adults.
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